Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on RAVEN RUSSIA LTD. We currently have 27 research reports from 4 professional analysts.
|13Mar17 07:00||RNS||Final Results|
|09Mar17 12:00||RNS||Preference Share Dividend|
|01Mar17 07:00||RNS||Acquisition Update|
|23Feb17 07:00||RNS||Scrip Dividend Circular|
|09Feb17 07:00||RNS||Preference Share Dividend|
|02Feb17 07:00||RNS||Block listing Interim Review|
|25Jan17 07:00||RNS||Director Declaration|
Frequency of research reports
Research reports on
RAVEN RUSSIA LTD
RAVEN RUSSIA LTD
N+1 Singer - Raven Russia Ltd - Portfolio re-pricing continues
13 Mar 17
Raven Russia produced underlying earnings ahead of our estimate, boosted by currency movements, an adjusted diluted NAV per share of 67.5¢ and a pleasing increase in the tender offer buyback to 2.5p per share for the full year. Lease maturities have been well managed with only a marginal increase in vacancy over the year, though average portfolio rents continued to re-price down towards market levels. There are reasonable grounds for believing the background is improving. Also, the much improved flexibility in the balance sheet enables the company to consider further value-enhancing property deals like that done recently in St Petersburg. On a 14% discount to forward NAV and an effective 5% yield the shares look good value.
N+1 Singer - Raven Russia Ltd - Short delay to St Petersburg portfolio acquisition
01 Mar 17
Due to administrative delays in satisfying certain escrow arrangements, Raven Russia has been unable to complete the acquisition of three properties in St Petersburg by the long stop date of 28 February 2017. A deed of amendment has been signed by all parties agreeing to extend the long stop date to 31 March 2017 with an option to extend for a further 20 business days. The company remains confident that the outstanding arrangements are purely administrative and that closing of this deal, which we believe to be significantly value enhancing, will be achieved. We are not changing our estimates on the basis of this delay on the grounds of materiality and probability of successful closing.
N+1 Singer - Morning Song 01-03-2017
01 Mar 17
Craneware (CRW LN) Interims to show momentum building | Elementis (ELM LN) Positioned to revive growth | James Fisher & Sons (FSJ LN) Solid results | MySale Group (MYSL LN) Growth platform established, momentum building | NCC Group (NCC LN) Rob Cotton steps down | Raven Russia Ltd (RUS LN) Short delay to St Petersburg portfolio acquisition
An opportune acquisition
24 Jan 17
Raven has announced the conditional acquisition of three properties in St Petersburg for RUB4.9bn (c $82m), below their replacement cost, which will generate rent of $13m in the first year of ownership (c 16% initial yield). The acquisition will be funded from existing cash reserves and is expected to be complete by the end of February. We maintain our previous forecasts pending the completion of the acquisition and the publication of Raven’s FY16 results on 13 March 2017.
Another positive verdict
20 Mar 17
Burford’s results for 2016 produced another outstanding set of figures. Revenue grew by 60% to $163.4m with strong growth in the litigation finance business and an additional boost from a secondary sale in the Petersen case. On an underlying basis net income grew to $114m, a 75% increase despite the investment in growing capacity which increased costs. A combination of ongoing investment and gains and increases on valuation saw the fair value of the litigation assets increase 67% to $559m, underpinned by a growth in invested capital to $394m. With the results statement there was an announcement of a further sale of 9% of the Petersen case at a valuation of 20 times the cost of investment.
N+1 Singer - Morning Song 22-03-2017
22 Mar 17
Carador Income Fund (CIFU LN) Premium rating restored, high levels of refinancing activity | Cello Group (CLL LN) Outlook getting brighter – watch Pulsar | Eckoh (ECK LN) Largest ever US secure payments win | eg solutions (EGS LN) Full year results in line | Futura Medical (FUM LN) Licensing deal for CSD500 in Portugal | Verona Pharma (VRP LN) Global agreement with QuintilesIMS to support development of RPL554 | Xaar (XAR LN) 2016 results slightly ahead, reduced visibility in 2017
N+1 Singer - N1S Trend spotting - Strategy update
08 Mar 17
In this new product we present some strategy theme updates arising out of our latest analysis of macro trends and economic data and our innovative Quant work. We also look at upcoming events and suggest topping up on some of our Best Ideas for 2017.